Participated · Series C · Aug 2026

Founded in February 2019, X Mile started as a staffing platform matching workers with employers in non-desk industries and has since broadened into software, AI tools, M&A advisory, and vehicle sales for operators. The platform now reports more than 1.2 million registered job seekers and over 30,000 client business locations. X Mile’s digital transformation platform for transportation and logistics operators has grown annual recurring revenue by more than 90% year-on-year. The company plans to expand its vertical AI product line for logistics, construction, and manufacturing, grow its M&A and business-support capabilities, and deepen partnerships with major corporations. Its recent Series C increases total funding to JPY6.96 billion and is intended to support product expansion and acquisitions that add complementary products and teams.

Participated · Series A · Aug 2026

Sinumy develops fully hands-free authentication technology that leverages smartphones' Bluetooth to identify people and automatically perform authentication for gates, payments, and access control. The company reports it has improved positioning accuracy from roughly 1.5 meters to about 10 centimeters, aiming to provide fast and spoof-resistant authentication even in crowded environments. In March it conducted a hands-free authentication gate demonstration at Shirokanedai Station in collaboration with Tokyo Metro and Toshiba. Following the recent financing, Sinumy plans productization and mass production preparation for smart gates and smart spots and intends to expand joint development and PoCs in gate, access control, and payment areas. The company also plans to hire development and business development personnel and strengthen its organization, and has appointed Tomoya Yonaga as Director and COO and Shunji Yamanaka as a UI/UX advisor.

Participated · Series B · Jun 2026

Triorb develops the TriOrb BASE, a ball-driven 360° omnidirectional mobility platform that uses three spheres and three motors at its base to achieve full-direction movement. The platform offers millimeter-level positioning and autonomous navigation via proprietary Visual SLAM and ROS2 modules and supports coordinated transport of multiple units. The standard model has a 300 kg payload capacity while a heavy-duty model carries up to 800 kg; the system can traverse 45 mm grooves, 10 mm steps, and gradients of approximately 9°. An optional battery provides about 3.5 hours of continuous operation. Target industries include automotive, semiconductors, steel manufacturing, warehousing and logistics, and construction, and a cited adoption example is Sugino Machine’s new mobile manipulator. The company has opened a Detroit base to support U.S. expansion.

Participated · Series C · Jun 2026

Oxford Quantum Circuits, founded as a spinout from Oxford University in 2017 and based in Reading, develops superconducting quantum computing hardware and supporting software. The company deploys its machines in data centres and offers access to customers and researchers as a cloud service. OQC targets business and government customers, citing demand from financial services, defence and security companies for secure quantum technology. It positions itself to move from long-term promise toward near-term commercial delivery and plans to scale internationally and advance its technology roadmap. The company recently strengthened its financial position by raising a £260 million Series C to accelerate commercialization and market expansion. No revenue or user metrics were disclosed in the provided article.

Participated · Seed · May 2026

Violet Therapeutics uses its proprietary CONNECT platform to map cellular interaction networks at scale and identify novel therapeutic targets implicated in neuroinflammation and neurodegeneration. Its lead program is a small-molecule candidate targeting EphB3, a receptor tyrosine kinase implicated in microglia–astrocyte signaling and synaptic loss. The company is preclinical-stage and plans IND-enabling studies for the EphB3 program, funded in part by the recently closed $4.75M seed extension. Violet was founded by Mass General Brigham Ventures with researchers from Brigham and Women’s Hospital and is based in Cambridge, MA. The company aims to build a pipeline of first-in-class CNS therapies that prevent synapse loss and restore synaptic function across neurodegenerative diseases.